BioMarin expects Q3 2026 pre-tax charges of $283 million for bought IPR&D expense
BMRN•BioMarin expects a $283 million pre-tax charge for bought IPR&D expense in Q3 2026, with an unfavorable $1.50 impact to GAAP and non-GAAP diluted EPS. For full-year 2026, it expects $320 million in pre-tax charges from the Alesta acquisition and an unfavorable $1.55 impact to diluted EPS.
1. Expected charges
BioMarin expects a $283 million pre-tax charge for bought IPR&D expense in Q3 2026, which it expects to have an unfavorable $1.50 impact on GAAP and non-GAAP diluted EPS. The company expects total pre-tax charges of $320 million from the Alesta acquisition for full-year 2026, with an unfavorable $1.55 impact on GAAP and non-GAAP diluted EPS.
